Anonymous
Guest
Anonymous
Guest
Overheard that a new OTC division to start soon with a sales contract force, any confirmation of this?
agree, we have great consumer brands that are floundering. No competitive point of difference, every one claims dermatologist recommended---
I do not totally agree. Once the patent's expire on the Rx brands this place will be a consumer OTC and hopefully an aesthetic company. I do agree that the Aesthetic BU is floundering. But if you look at the facts the long term prospects and lack of pipeline will at some point put an end to the Rx side of the business. They waited so long to launch some of the Rx products that we only have less than three years of patent life left on some of them. So do the math and enjoy the ride until it comes to a stop.
And you really think Nestle will just let the Rx side die a slow death? You obviously do not understand what Business Development and R&D mean to a pharma company. Don't want people like you around so its best you probably leave, why wait for the end if you are so sure you know the ending already? good riddance.
And you really think Nestle will just let the Rx side die a slow death? You obviously do not understand what Business Development and R&D mean to a pharma company. Don't want people like you around so its best you probably leave, why wait for the end if you are so sure you know the ending already? good riddance.
It's interesting to read backWell you are ignoring the history of this place my friend. They invested about 10% or more into R and D over the last 25 years. It might be higher if you take out the regulatory costs and all they have developed is Differin and Epiduo ( one new chemical entity in 30 years) everything else came out of acquisitions. Rx products and pipeline is drying up and the one poster who said some of the exclusivity is only 3 years such as the Ivermectin product is spot on. Keep drinking the Koolaid but they are already positioning the place for the long term aesthetics and OTC. Facts are facts.
It's unfortunate but the leadership in charge of this division made questionable decisions in the beginning. middle and end of the active promotion period. By some appearances, based on erroneous decision making, it could be assumed that the failure of the sales force was intentionally orchestrated to dissolve the contract sales force. Galderma had the right to either continue the contract, bring over the Inventiv sales force or dissolve the division altogether. There is no question or argument that G could make whichever decision was best for the organization. "That's business". The manner and execution of the decision however, speaks volumes to the moral fiber of the leadership of the OTC division.